Theorem Clinical Research

Drug Sponsors

Emergent BioSolutions completes acquisition of Cangene

Monday, February 24, 2014 10:13 AM

Emergent BioSolutions, a specialty pharmaceutical company offering specialized products to healthcare providers and governments, has completed its acquisition of Cangene for $222 million in cash. After payment by Cangene of transaction related costs, Emergent expects to receive approximately $40 million of cash from Cangene in connection with closing. The completion of the acquisition follows the successful conclusion of all closing conditions, including approval by the Ontario Superior Court of Justice and a positive vote by Cangene shareholders at a special shareholder meeting held Feb. 12. The transaction is consistent with Emergent’s growth plan in that it diversifies the company’s revenue mix, adds commercial product sales and contributes to earnings growth.

More... »


Actavis to acquire Forest Laboratories for $25 billion

Tuesday, February 18, 2014 10:39 AM

Dublin-based Actavis has agreed to acquire Forest Laboratories of New York for a combination of cash and equity valued at approximately $25 billion.

More... »


Report: Strong Q4 M&A momentum expected to continue into 2014

Wednesday, February 12, 2014 01:44 PM

Pharmaceutical and life sciences (PLS) merger and acquisition volume and value increased in the fourth quarter of 2013, finishing the year for deal activity on a high note,according to Pharmaceutical and Life Sciences Deals Insights Quarterly, a quarterly analysis of M&A trends and outlook for the PLS sector issued by PwC. PwC’s Health Industries Group is an advisor to public and private organizations across the health industries.

More... »

Mallinckrodt to acquire Cadence Pharmaceuticalsfor $1.3 billion

Wednesday, February 12, 2014 01:26 PM

A subsidiary of Mallinckrodt, a global specialty pharmaceuticals company, will acquire Cadence Pharmaceuticals, and will commence a tender offer to acquire all outstanding shares for $14 per share in cash, or approximately $1.3 billion, a 32% premium to the trailing 30-trading-day volume weighted average price of $10.62 per share.

More... »

Mast Therapeutics to acquire Aires Pharmaceuticals

Monday, February 10, 2014 11:35 AM

Mast Therapeutics has entered into a definitive agreement to acquire Aires Pharmaceuticals, a privately-held, clinical stage pharmaceutical company developing therapies to treat pulmonary vascular disorders such as pulmonary arterial hypertension and pulmonary hypertension due to heart failure. Aires' lead product, AIR001, is an intermittently nebulized formulation of nitrite and has Orphan Drug status with the FDA and the EMA for the treatment of pulmonary arterial hypertension.

More... »

Pelican Products acquires Cool Logistics

Friday, February 7, 2014 02:09 PM

Behrman Capital, a private equity investment firm based in New York and San Francisco, announced that its portfolio company Pelican Products, a design and manufacturer of high-performance protective case solutions and advanced portable lighting systems, has acquired U.K.-based Cool Logistics, a provider of temperature controlled packaging solutions. Financial terms of the transaction have not been disclosed.

More... »

Myriad Genetics to acquire Crescendo Bioscience

Thursday, February 6, 2014 12:38 PM

Myriad Genetics, a molecular diagnostic company, has entered into a definitive agreement to acquire Crescendo Bioscience, a global provider of autoimmune diagnostics, for $270 million in cash which will be reduced by $25 million for the repayment of a loan made to Crescendo and customary adjustments in accordance with the acquisition agreement.

More... »

Report: Pharmaceutical firms are humanizing their brands

Thursday, February 6, 2014 11:45 AM

By 2018, it is estimated the global pharmaceutical market will be worth more than $1.3 trillion. To corner their share of profits, established drug companies have to fight fierce competition from generic products, adhere to stringent government regulations and sway a consumer base that is better informed than ever before.

More... »

Bristol-Myers Squibb completes sale of global diabetes business to AstraZeneca

Monday, February 3, 2014 08:51 AM

Bristol-Myers Squibb has completed the previously announced sale of its global diabetes business to AstraZeneca.

More... »

Wilex to implement cost-cutting, reduce workforce 80%

Friday, January 31, 2014 12:54 PM

Wilex, a biopharmaceutical company based in Munich, Germany, will implement extensive cost-cutting measures and focus on contract research and the ADC technology at its subsidiary Heidelberg Pharma. This decision was taken with the approval of the company's supervisory board.

More... »

Subscribe to The CenterWatch Monthly
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

October 20

Toronto Star, with FDA data, exposes weaknesses in Health Canada's clinical trial, inspection oversight

Crowdsourcing effort aims to fund updated online social media guide for sponsor interaction with patients

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

September

Today's fastest, most economical sponsors
Standout sponsors reveal how they shorten regulatory, clinical cycle times

From the trenches: Sites' eye view of state of the industry
CW’s first site focus groups uncover frustration with 'progress,' but a passion for their mission

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs